{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:29:16Z","timestamp":1790882956315,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the widespread adoption of chemotherapy, drug resistance has been the major obstacle to tumor elimination in cancer patients. Our aim was to explore the role of TGF-\u03b2 in osteosarcoma-associated chemoresistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a cytotoxicity analysis of methotrexate (MTX) and cisplatin (CIS) in TGF-\u03b2-treated osteosarcoma cells. Then, the metabolite profile of the core metabolic energy pathways in Saos-2 and MG-63 cell extracts was analyzed by <jats:sup>1<\/jats:sup>H-NMR. We detected the expression of succinate dehydrogenase (SDH), STAT1, and hypoxia-inducible factor 1\u03b1 (HIF1\u03b1) in TGF-\u03b2-treated osteosarcoma cells and further tested the effects of these molecules on the cytotoxicity induced by chemotherapeutic agents. Using in vivo experiments, we examined the tumor growth and survival time of Saos-2-bearing mice treated with a combination of chemotherapeutic agents and a HIF1\u03b1 inhibitor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The metabolic analysis revealed enhanced succinate production in osteosarcoma cells after TGF-\u03b2 treatment. We further found a decrease in SDH expression and an increase in HIF1\u03b1 expression in TGF-\u03b2-treated osteosarcoma cells. Consistently, blockade of SDH efficiently enhanced the resistance of Saos-2 and MG-63 cells to MTX and CIS. Additionally, a HIF1\u03b1 inhibitor significantly strengthened the anticancer efficacy of the chemotherapeutic drugs in mice with osteosarcoma cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study demonstrated that TGF-\u03b2 attenuated the expression of SDH by reducing the transcription factor STAT1. The reduction in SDH then caused the upregulation of HIF1\u03b1, thereby rerouting glucose metabolism and aggravating chemoresistance in osteosarcoma cells. Linking tumor cell metabolism to the formation of chemotherapy resistance, our study may guide the development of additional treatments for osteosarcoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08954-7","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T12:03:39Z","timestamp":1636632219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["TGF-\u03b2 protects osteosarcoma cells from chemotherapeutic cytotoxicity in a SDH\/HIF1\u03b1 dependent manner"],"prefix":"10.1186","volume":"21","author":[{"given":"Yangbo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"issue":"Suppl 7","key":"8954_CR1","doi-asserted-by":"publisher","first-page":"vii320","DOI":"10.1093\/annonc\/mdq276","volume":"21","author":"J Ritter","year":"2010","unstructured":"Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21(Suppl 7):vii320\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdq276.","journal-title":"Ann Oncol"},{"issue":"18","key":"8954_CR2","doi-asserted-by":"publisher","first-page":"6885","DOI":"10.3390\/ijms21186885","volume":"21","author":"I Lilienthal","year":"2020","unstructured":"Lilienthal I, Herold N. Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies. Int J Mol Sci. 2020;21(18):6885. https:\/\/doi.org\/10.3390\/ijms21186885.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"8954_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/14737140.2018.1413939","volume":"18","author":"DJ Harrison","year":"2018","unstructured":"Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39\u201350. https:\/\/doi.org\/10.1080\/14737140.2018.1413939.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"27","key":"8954_CR4","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","volume":"33","author":"MS Isakoff","year":"2015","unstructured":"Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029\u201335. https:\/\/doi.org\/10.1200\/JCO.2014.59.4895.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8954_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.canlet.2014.03.013","volume":"347","author":"Q Wu","year":"2014","unstructured":"Wu Q, Yang Z, Nie Y, Shi Y, Fan D. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 2014;347(2):159\u201366. https:\/\/doi.org\/10.1016\/j.canlet.2014.03.013.","journal-title":"Cancer Lett"},{"issue":"5","key":"8954_CR6","doi-asserted-by":"publisher","first-page":"e0152090","DOI":"10.1371\/journal.pone.0152090","volume":"11","author":"C Pan","year":"2016","unstructured":"Pan C, Wang X, Shi K, Zheng Y, Li J, Chen Y, et al. MiR-122 reverses the doxorubicin-resistance in hepatocellular carcinoma cells through regulating the tumor metabolism. PLoS One. 2016;11(5):e0152090. https:\/\/doi.org\/10.1371\/journal.pone.0152090.","journal-title":"PLoS One"},{"key":"8954_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.critrevonc.2017.03.026","volume":"114","author":"C Grasso","year":"2017","unstructured":"Grasso C, Jansen G, Giovannetti E. Drug resistance in pancreatic cancer: impact of altered energy metabolism. Crit Rev Oncol Hematol. 2017;114:139\u201352. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.03.026.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"8954_CR8","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.3390\/cancers12082252","volume":"12","author":"E Varghese","year":"2020","unstructured":"Varghese E, Samuel SM, L\u00ed\u0161kov\u00e1 A, Samec M, Kubatka P, B\u00fcsselberg D. Targeting glucose metabolism to overcome resistance to anticancer chemotherapy in breast Cancer. Cancers (Basel). 2020;12(8):2252. https:\/\/doi.org\/10.3390\/cancers12082252.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"8954_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bbrc.2013.09.041","volume":"440","author":"JW Min","year":"2013","unstructured":"Min JW, Kim KI, Kim HA, Kim EK, Noh WC, Jeon HB, et al. INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells. Biochem Biophys Res Commun. 2013;440(1):137\u201342. https:\/\/doi.org\/10.1016\/j.bbrc.2013.09.041.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"8954_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.cell.2015.01.043","volume":"160","author":"N Oshimori","year":"2015","unstructured":"Oshimori N, Oristian D, Fuchs E. TGF-\u03b2 promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell. 2015;160(5):963\u201376. https:\/\/doi.org\/10.1016\/j.cell.2015.01.043.","journal-title":"Cell"},{"issue":"1","key":"8954_CR11","doi-asserted-by":"publisher","first-page":"15870","DOI":"10.1038\/ncomms15870","volume":"8","author":"J Cai","year":"2017","unstructured":"Cai J, Fang L, Huang Y, Li R, Xu X, Hu Z, et al. Simultaneous overactivation of Wnt\/\u03b2-catenin and TGF\u03b2 signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC. Nat Commun. 2017;8(1):15870. https:\/\/doi.org\/10.1038\/ncomms15870.","journal-title":"Nat Commun"},{"issue":"570","key":"8954_CR12","doi-asserted-by":"publisher","first-page":"eaau8544","DOI":"10.1126\/scisignal.aau8544","volume":"12","author":"Y Katsuno","year":"2019","unstructured":"Katsuno Y, Meyer DS, Zhang Z, Shokat KM, Akhurst RJ, Miyazono K, et al. Chronic TGF-\u03b2 exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. Sci Signal. 2019;12(570):eaau8544. https:\/\/doi.org\/10.1126\/scisignal.aau8544.","journal-title":"Sci Signal"},{"issue":"24","key":"8954_CR13","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1080\/15384101.2019.1693120","volume":"18","author":"E Bhagyaraj","year":"2019","unstructured":"Bhagyaraj E, Ahuja N, Kumar S, Tiwari D, Gupta S, Nanduri R, et al. TGF-\u03b2 induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR. Cell Cycle. 2019;18(24):3589\u2013602. https:\/\/doi.org\/10.1080\/15384101.2019.1693120.","journal-title":"Cell Cycle"},{"issue":"17","key":"8954_CR14","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1038\/s41388-018-0655-8","volume":"38","author":"V Tripathi","year":"2019","unstructured":"Tripathi V, Shin JH, Stuelten CH, Zhang YE. TGF-\u03b2-induced alternative splicing of TAK1 promotes EMT and drug resistance. Oncogene. 2019;38(17):3185\u2013200. https:\/\/doi.org\/10.1038\/s41388-018-0655-8.","journal-title":"Oncogene"},{"issue":"10","key":"8954_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3810","volume":"11","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst RJ, Hata A. Targeting the TGF\u03b2 signalling pathway in disease. Nat Rev Drug Discov. 2012;11(10):790\u2013811. https:\/\/doi.org\/10.1038\/nrd3810.","journal-title":"Nat Rev Drug Discov"},{"issue":"35","key":"8954_CR16","doi-asserted-by":"publisher","first-page":"15535","DOI":"10.1073\/pnas.1009472107","volume":"107","author":"Z Yao","year":"2010","unstructured":"Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A. 2010;107(35):15535\u201340. https:\/\/doi.org\/10.1073\/pnas.1009472107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"8954_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/molecules21070965","volume":"21","author":"B Du","year":"2016","unstructured":"Du B, Shim JS. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in Cancer. Molecules. 2016;21(7):965. https:\/\/doi.org\/10.3390\/molecules21070965.","journal-title":"Molecules"},{"issue":"1","key":"8954_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","volume":"3","author":"S Colak","year":"2017","unstructured":"Colak S, Ten Dijke P. Targeting TGF-\u03b2 signaling in Cancer. Trends Cancer. 2017;3(1):56\u201371. https:\/\/doi.org\/10.1016\/j.trecan.2016.11.008.","journal-title":"Trends Cancer"},{"issue":"11","key":"8954_CR19","doi-asserted-by":"publisher","first-page":"5877","DOI":"10.1021\/pr100635n","volume":"9","author":"IF Duarte","year":"2010","unstructured":"Duarte IF, Lamego I, Marques J, Marques MP, Blaise BJ, Gil AM. Nuclear magnetic resonance (NMR) study of the effect of cisplatin on the metabolic profile of MG-63 osteosarcoma cells. J Proteome Res. 2010;9(11):5877\u201386. https:\/\/doi.org\/10.1021\/pr100635n.","journal-title":"J Proteome Res"},{"issue":"2","key":"8954_CR20","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1021\/acs.jproteome.9b00635","volume":"19","author":"C Lin","year":"2020","unstructured":"Lin C, Dong J, Wei Z, Cheng KK, Li J, You S, et al. 1H NMR-based metabolic profiles delineate the anticancer effect of vitamin C and Oxaliplatin on hepatocellular carcinoma cells. J Proteome Res. 2020;19(2):781\u201393. https:\/\/doi.org\/10.1021\/acs.jproteome.9b00635.","journal-title":"J Proteome Res"},{"issue":"1","key":"8954_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/nbm.740","volume":"15","author":"JE Le Belle","year":"2002","unstructured":"Le Belle JE, Harris NG, Williams SR, Bhakoo KK. A comparison of cell and tissue extraction techniques using high-resolution 1H-NMR spectroscopy. NMR Biomed. 2002;15(1):37\u201344. https:\/\/doi.org\/10.1002\/nbm.740.","journal-title":"NMR Biomed"},{"issue":"11","key":"8954_CR22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nrc3603","volume":"13","author":"M Pickup","year":"2013","unstructured":"Pickup M, Novitskiy S, Moses HL. The roles of TGF\u03b2 in the tumour microenvironment. Nat Rev Cancer. 2013;13(11):788\u201399. https:\/\/doi.org\/10.1038\/nrc3603.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"8954_CR23","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/bph.13422","volume":"173","author":"B Bhattacharya","year":"2016","unstructured":"Bhattacharya B, Mohd Omar MF, Soong R. The Warburg effect and drug resistance. Br J Pharmacol. 2016;173(6):970\u20139. https:\/\/doi.org\/10.1111\/bph.13422.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"8954_CR24","doi-asserted-by":"publisher","first-page":"a022137","DOI":"10.1101\/cshperspect.a022137","volume":"9","author":"K Luo","year":"2017","unstructured":"Luo K. Signaling Cross Talk between TGF-\u03b2\/Smad and Other Signaling Pathways. Cold Spring Harb Perspect Biol. 2017;9(1):a022137. Published 2017 Jan 3. https:\/\/doi.org\/10.1101\/cshperspect.a022137.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"10","key":"8954_CR25","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1172\/JCI84431","volume":"126","author":"SE Corcoran","year":"2016","unstructured":"Corcoran SE, O'Neill LA. HIF1\u03b1 and metabolic reprogramming in inflammation. J Clin Invest. 2016;126(10):3699\u2013707. https:\/\/doi.org\/10.1172\/JCI84431.","journal-title":"J Clin Invest"},{"issue":"12","key":"8954_CR26","doi-asserted-by":"publisher","first-page":"a022277","DOI":"10.1101\/cshperspect.a022277","volume":"9","author":"J Seoane","year":"2017","unstructured":"Seoane J, Gomis RR. TGF-\u03b2 family signaling in tumor suppression and Cancer progression. Cold Spring Harb Perspect Biol. 2017;9(12):a022277. https:\/\/doi.org\/10.1101\/cshperspect.a022277.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"18","key":"8954_CR27","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.4161\/cc.26034","volume":"12","author":"D Brunen","year":"2013","unstructured":"Brunen D, Willems SM, Kellner U, Midgley R, Simon I, Bernards R. TGF-\u03b2: an emerging player in drug resistance. Cell Cycle. 2013;12(18):2960\u20138. https:\/\/doi.org\/10.4161\/cc.26034.","journal-title":"Cell Cycle"},{"issue":"5","key":"8954_CR28","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200. https:\/\/doi.org\/10.1126\/sciadv.1600200.","journal-title":"Sci Adv"},{"issue":"1","key":"8954_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of Cancer metabolism. Cell Metab. 2016;23(1):27\u201347. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.006.","journal-title":"Cell Metab"},{"issue":"13","key":"8954_CR30","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/0008-5472.CAN-11-0127","volume":"71","author":"Y Zhao","year":"2011","unstructured":"Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP, Wilson GL, et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res. 2011;71(13):4585\u201397. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0127.","journal-title":"Cancer Res"},{"issue":"6","key":"8954_CR31","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/j.1349-7006.2010.01562.x","volume":"101","author":"HS Shi","year":"2010","unstructured":"Shi HS, Li D, Zhang J, Wang YS, Yang L, Zhang HL, et al. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci. 2010;101(6):1447\u201353. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01562.x.","journal-title":"Cancer Sci"},{"issue":"9","key":"8954_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1593\/neo.10526","volume":"12","author":"B Le Calv\u00e9","year":"2010","unstructured":"Le Calv\u00e9 B, Rynkowski M, Le Mercier M, Bruy\u00e8re C, Lonez C, Gras T, et al. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia. 2010;12(9):727\u201339. https:\/\/doi.org\/10.1593\/neo.10526.","journal-title":"Neoplasia"},{"issue":"1","key":"8954_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/jnc.13111","volume":"134","author":"X Zhou","year":"2015","unstructured":"Zhou X, Z\u00f6ller T, Krieglstein K, Spittau B. TGF\u03b21 inhibits IFN\u03b3-mediated microglia activation and protects mDA neurons from IFN\u03b3-driven neurotoxicity. J Neurochem. 2015;134(1):125\u201334. https:\/\/doi.org\/10.1111\/jnc.13111.","journal-title":"J Neurochem"},{"issue":"7","key":"8954_CR34","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.4049\/jimmunol.178.7.4284","volume":"178","author":"C Reardon","year":"2007","unstructured":"Reardon C, McKay DM. TGF-beta suppresses IFN-gamma-STAT1-dependent gene transcription by enhancing STAT1-PIAS1 interactions in epithelia but not monocytes\/macrophages. J Immunol. 2007;178(7):4284\u201395. https:\/\/doi.org\/10.4049\/jimmunol.178.7.4284.","journal-title":"J Immunol"},{"issue":"8","key":"8954_CR35","doi-asserted-by":"publisher","first-page":"13174","DOI":"10.18632\/oncotarget.14485","volume":"8","author":"X Mu","year":"2017","unstructured":"Mu X, Zhao T, Xu C, Shi W, Geng B, Shen J, et al. Oncometabolite succinate promotes angiogenesis by upregulating VEGF expression through GPR91-mediated STAT3 and ERK activation. Oncotarget. 2017;8(8):13174\u201385. https:\/\/doi.org\/10.18632\/oncotarget.14485.","journal-title":"Oncotarget"},{"issue":"12","key":"8954_CR36","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1101\/gad.191056.112","volume":"26","author":"M Xiao","year":"2012","unstructured":"Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, et al. Inhibition of \u03b1-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012;26(12):1326\u201338. https:\/\/doi.org\/10.1101\/gad.191056.112.","journal-title":"Genes Dev"},{"issue":"1","key":"8954_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11912-019-0752-z","volume":"21","author":"J Fallah","year":"2019","unstructured":"Fallah J, Rini BI. HIF inhibitors: status of current clinical development. Curr Oncol Rep. 2019;21(1):6. https:\/\/doi.org\/10.1007\/s11912-019-0752-z.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"8954_CR38","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/cam4.991","volume":"6","author":"T Sowa","year":"2017","unstructured":"Sowa T, Menju T, Chen-Yoshikawa TF, Takahashi K, Nishikawa S, Nakanishi T, et al. Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression. Cancer Med. 2017;6(1):288\u201397. https:\/\/doi.org\/10.1002\/cam4.991.","journal-title":"Cancer Med"},{"issue":"3","key":"8954_CR39","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3892\/or.2015.4536","volume":"35","author":"Y Sun","year":"2016","unstructured":"Sun Y, Guan Z, Liang L, Cheng Y, Zhou J, Li J, et al. HIF-1\u03b1\/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer. Oncol Rep. 2016;35(3):1549\u201356. https:\/\/doi.org\/10.3892\/or.2015.4536.","journal-title":"Oncol Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08954-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08954-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08954-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T12:06:02Z","timestamp":1636632362000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08954-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8954"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08954-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]},"assertion":[{"value":"26 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University. Written informed consent was attained from all individual participants, and all methods were performed according to the Declaration of Helsinki. All animal experiments were approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University, according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1200"}}